244 related articles for article (PubMed ID: 27628195)
1. A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer.
Han B; Jung JY; Kim HS; Cho JW; Kim KC; Lim H; Kang HS; Ha HI; Kim MJ; Kim JH; Choi DR; Jang G; Kim JH; Song H; Zang DY
Cancer Chemother Pharmacol; 2016 Nov; 78(5):949-958. PubMed ID: 27628195
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
[TBL] [Abstract][Full Text] [Related]
3. Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer.
Zang DY; Yang DH; Kim MJ; Jang KM; Hwang SW; Yoo KS; Han T; Kim HY; Kim HJ; Kwon JH; Song HH; Park S; Jung JY; Kim HS; Kim JH
Cancer Chemother Pharmacol; 2009 Oct; 64(5):877-83. PubMed ID: 19190908
[TBL] [Abstract][Full Text] [Related]
4. Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma.
Yanagimoto H; Satoi S; Sho M; Akahori T; Yamamoto T; Hirooka S; Yamaki S; Kotsuka M; Ryota H; Kinoshita S; Nishiwada S; Nagai M; Ikeda N; Tsuta K; Nakajima Y; Kon M
Cancer Chemother Pharmacol; 2016 Jan; 77(1):35-41. PubMed ID: 26645403
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer.
Oh SY; Ju YT; Choi SK; Ha CY; Lee WS; Kim HG; Lee GW; Kwon HC; Kang JH
Invest New Drugs; 2011 Oct; 29(5):1050-6. PubMed ID: 20238142
[TBL] [Abstract][Full Text] [Related]
6. Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients.
Goldwasser F; Gross-Goupil M; Tigaud JM; Di Palma M; Marceau-Suissa J; Wasserman E; Yovine A; Misset JL; Cvitkovic E
Ann Oncol; 2000 Nov; 11(11):1463-70. PubMed ID: 11142487
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer.
Choi YH; Kim TW; Lee SS; Hong YS; Ryu MH; Lee JL; Chang HM; Kang YK
Cancer Chemother Pharmacol; 2011 Oct; 68(4):905-12. PubMed ID: 21290246
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
[TBL] [Abstract][Full Text] [Related]
9. Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study.
Sheikh HY; Valle JW; Palmer K; Sjursen A; Craven O; Wilson G; Swindell R; Saunders MP
Br J Cancer; 2007 Jan; 96(1):38-43. PubMed ID: 17213824
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer.
Sym SJ; Hong J; Jung M; Park J; Cho EK; Lee WK; Chung M; Kim HS; Lee JH; Shin DB
Cancer Chemother Pharmacol; 2012 Aug; 70(2):277-84. PubMed ID: 22752217
[TBL] [Abstract][Full Text] [Related]
11. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.
Wasserman E; Cuvier C; Lokiec F; Goldwasser F; Kalla S; Méry-Mignard D; Ouldkaci M; Besmaine A; Dupont-André G; Mahjoubi M; Marty M; Misset JL; Cvitkovic E
J Clin Oncol; 1999 Jun; 17(6):1751-9. PubMed ID: 10561212
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer.
Moehler M; Mahlberg R; Heinemann V; Obermannová R; Kubala E; Melichar B; Weinmann A; Scigalla P; Tesařová M; Janda P; Hédouin-Biville F; Mansoor W
Gastric Cancer; 2017 Mar; 20(2):358-367. PubMed ID: 27255289
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
Oshita F; Yamada K; Kato Y; Ikehara M; Noda K; Tanaka G; Nomura I; Suzuki R; Saito H
Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
[TBL] [Abstract][Full Text] [Related]
14. A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study.
Sato Y; Hirakawa M; Ohnuma H; Takahashi M; Okamoto T; Okamoto K; Miyamoto H; Muguruma N; Furuhata T; Takemasa I; Kato J; Takayama T
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1133-1139. PubMed ID: 29038850
[TBL] [Abstract][Full Text] [Related]
15. Dose escalating clinical study of high dose infusional 5-fluorouracil and leukovorin (AIO regimen) plus alternate weekly administration of oxaliplatin and irinotecan in patients with advanced tumors of the gastrointestinal tract.
Gkioulbasanis I; Souglakos J; Vardakis N; Kotsakis A; Saridaki Z; Kentepozidis N; Polyzos A; Giassas S; Ignatiadis M; Bozionelou V; Christophylakis C; Georgoulias V
J BUON; 2007; 12(2):197-202. PubMed ID: 17600872
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Ueda Y; Yamagishi H; Ichikawa D; Morii J; Koizumi K; Kakihara N; Shimotsuma M; Takenaka A; Yamashita T; Kurioka H; Nishiyama M; Morita S; Nakamura K; Sakamoto J
Oncology; 2005; 69(3):261-8. PubMed ID: 16138002
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer.
Hoff PM; Saad ED; Pazdur R; Wolff R; Lassere Y; Bogaard KR; Abbruzzese JL
Invest New Drugs; 2004 Aug; 22(3):307-13. PubMed ID: 15122078
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer.
Inokuchi M; Yamashita T; Yamada H; Kojima K; Ichikawa W; Nihei Z; Kawano T; Sugihara K
Br J Cancer; 2006 Apr; 94(8):1130-5. PubMed ID: 16570038
[TBL] [Abstract][Full Text] [Related]
19. A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer.
Sato Y; Ohnuma H; Hirakawa M; Takahashi M; Osuga T; Okagawa Y; Murase K; Takada K; Kawano Y; Iyama S; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Okita K; Mizuguchi T; Furuhata T; Hirata K; Kato J
Cancer Chemother Pharmacol; 2015 Mar; 75(3):587-94. PubMed ID: 25577134
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer.
Yamada Y; Yasui H; Goto A; Arai T; Ura T; Hamaguchi T; Muro K; Shimada Y; Shirao K
Int J Clin Oncol; 2003 Dec; 8(6):374-80. PubMed ID: 14663640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
